Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Dividends payables (2025)

Oramed Pharmaceuticals' Dividends payables history spans 1 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Dividends payables changed N/A year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, changed N/A, while the annual FY2025 figure was $10.6 million, N/A changed from the prior year.
  • Dividends payables reached $10.6 million in Q4 2025 per ORMP's latest filing.
  • In the past five years, Dividends payables ranged from a high of $10.6 million in Q4 2025 to a low of $10.6 million in Q4 2025.